Advertisement
| pathalys pharma: Aerosol Science and Technology David S. Ensor, 2011-10-06 Aerosol Science and Technology: History and Reviews captures an exciting slice of history in the evolution of aerosol science. It presents in-depth biographies of four leading international aerosol researchers and highlights pivotal research institutions in New York, Minnesota, and Austria. One collection of chapters reflects on the legacy of the Pasadena smog experiment, while another presents a fascinating overview of military applications and nuclear aerosols. Finally, prominent researchers offer detailed reviews of aerosol measurement, processes, experiments, and technology that changed the face of aerosol science. This volume is the third in a series and is supported by the American Association for Aerosol Research (AAAR) History Working Group, whose goal is to produce archival books from its symposiums on the history of aerosol science to ensure a lasting record. It is based on papers presented at the Third Aerosol History Symposium on September 8 and 9, 2006, in St. Paul, Minnesota, USA. |
| pathalys pharma: Immuno-ophthalmology Uwe Pleyer, Manfred Zierhut, Wolfgang Behrens-Baumann, 1999-01-01 Although considerable light has been shed on the mechanisms of ocular immunity over the past 20 years, a complete understanding still eludes our grasp. To many ophthalmologists immunology itself is a comparatively new field. This volume will bring the latest findings in immunological research and the resulting new therapy methods to the ophthalmologist in practice. The scope of the topics goes from general principles of immuno-ophthalmology to more specific ones such as immunology of corneal transplantation or immune regulation of uveoretinal inflammation. With its broad scope of contributions, this publication will not only be significant to the ophthalmologist, but also to pediatricians, specialists in internal medicine as well as dermatologists confronted with eye diseases. |
| pathalys pharma: Molecular Nuclear Medicine L.E. Feinendegen, W.W. Shreeve, W.C. Eckelman, Yong Whee Bahk, H.N. Jr. Wagner, 2012-12-06 Nuclear Medicine techniques have advanced to such a degree that biochemical transparency of the human body has reached the doorstep of medical application. The book gives background, techniques and examples in an interdisciplinary approach to quantify biochemical reactions in vivo by regional imaging and in vitro analyses. The goal is to assess in vivo biochemical homeostatic circuits under control by genes and protein interactions. It becomes apparent how nuclear medicine can aid clinical researchers and practitioners, human geneticists and pharmacologists in understanding (and affecting) gene-phenotype relationships operating in vivo and thus can help eventually to bring functional genomics and proteomics to clinical medicine. |
| pathalys pharma: The Five Wounds Kirstin Valdez Quade, 2022-01-25 It’s Holy Week in the small town of Las Penas, New Mexico, and thirty-three-year-old unemployed Amadeo Padilla has been given the part of Jesus in the Good Friday procession. He is preparing feverishly for this role when his fifteen-year-old daughter Angel shows up pregnant on his doorstep and disrupts his plans for personal redemption. With weeks to go until her due date, tough, ebullient Angel has fled her mother’s house, setting her life on a startling new path. Vivid, tender, funny, and beautifully rendered, The Five Wounds spans the baby’s first year as five generations of the Padilla family converge: Amadeo’s mother, Yolanda, reeling from a recent discovery; Angel’s mother, Marissa, whom Angel isn’t speaking to; and disapproving Tíve, Yolanda’s uncle and keeper of the family’s history. Each brings expectations that Amadeo, who often solves his problems with a beer in his hand, doesn’t think he can live up to. The Five Wounds is a miraculous debut novel from a writer whose stories have been hailed as “legitimate masterpieces” (New York Times). Kirstin Valdez Quade conjures characters that will linger long after the final page, bringing to life their struggles to parent children they may not be equipped to save. |
| pathalys pharma: Journeys North Barney Scout Mann, 2020-08-01 2020 Banff Mountain Book Competition Finalist in Adventure Travel In Journeys North, legendary trail angel, thru hiker, and former PCTA board member Barney Scout Mann spins a compelling tale of six hikers on the Pacific Crest Trail in 2007 as they walk from Mexico to Canada. This ensemble story unfolds as these half-dozen hikers--including Barney and his wife, Sandy--trod north, slowly forming relationships and revealing their deepest secrets and aspirations. They face a once-in-a-generation drought and early severe winter storms that test their will in this bare-knuckled adventure. In fact, only a third of all the hikers who set out on the trail that year would finish. As the group approaches Canada, a storm rages. How will these very different hikers, ranging in age, gender, and background, respond to the hardship and suffering ahead of them? Can they all make the final 60-mile push through freezing temperatures, sleet, and snow, or will some reach their breaking point? Journeys North is a story of grit, compassion, and the relationships people forge when they strive toward a common goal. |
| pathalys pharma: Pharma Gerald Posner, 2020-03-10 Award-winning journalist and New York Times bestselling author Gerald Posner reveals the heroes and villains of the trillion-dollar-a-year pharmaceutical industry and delivers “a withering and encyclopedic indictment of a drug industry that often seems to prioritize profits over patients (The New York Times Book Review). Pharmaceutical breakthroughs such as antibiotics and vaccines rank among some of the greatest advancements in human history. Yet exorbitant prices for life-saving drugs, safety recalls affecting tens of millions of Americans, and soaring rates of addiction and overdose on prescription opioids have caused many to lose faith in drug companies. Now, Americans are demanding a national reckoning with a monolithic industry. “Gerald’s dogged reporting, sets Pharma apart from all books on this subject” (The Washington Standard) as we are introduced to brilliant scientists, incorruptible government regulators, and brave whistleblowers facing off against company executives often blinded by greed. A business that profits from treating ills can create far deadlier problems than it cures. Addictive products are part of the industry’s DNA, from the days when corner drugstores sold morphine, heroin, and cocaine, to the past two decades of dangerously overprescribed opioids. Pharma also uncovers the real story of the Sacklers, the family that became one of America’s wealthiest from the success of OxyContin, their blockbuster narcotic painkiller at the center of the opioid crisis. Relying on thousands of pages of government and corporate archives, dozens of hours of interviews with insiders, and previously classified FBI files, Posner exposes the secrets of the Sacklers’ rise to power—revelations that have long been buried under a byzantine web of interlocking companies with ever-changing names and hidden owners. The unexpected twists and turns of the Sackler family saga are told against the startling chronicle of a powerful industry that sits at the intersection of public health and profits. “Explosively, even addictively, readable” (Booklist, starred review), Pharma reveals how and why American drug companies have put earnings ahead of patients. |
| pathalys pharma: Drug Truths John L. LaMattina, 2012-03-02 This book answers the questions about the process and costs of pharmaceutical R & D in a compelling narrative focused on the discovery and development of important new medicines. It gives an insider's account of the pharmaceutical industry drug discovery process, the very real costs of misperceptions about the industry, the high stakes--both economic and scientific--of developing drugs, the triumphs that come when new compounds reach the market and save lives, and the despair that follows when new compounds fail. In the book, John LaMattina, former president of Pfizer Global Research and Development, weaves themes critical to a vital drug discovery environment in the context. This is a story that Dr. LaMattina is uniquely qualified to tell. |
| pathalys pharma: Our Daily Meds Melody Petersen, 2009-03-03 Our Daily Meds shows how corporate salesmanship has triumphed over science inside the biggest pharmaceutical companies and, in turn, how this promotion-driven industry has taken over the practice of medicine. |
| pathalys pharma: The Global Pharmaceutical Industry Daniel Hoffman, Allan Bowditch, 2020-07-06 The pharmaceutical industry, long thought of as a recession-proof investment, now faces a day of reckoning. The reasons for this impending downfall are not hard to discern. The prices the industry charges for its prescription drugs have escalated at four to five times the cost-of-living increases during the past two decades and have reached a point where 30% of Americans must choose between filling a prescription, paying for housing, and buying food. This has brought about public pressure on governments around the world to control drug prices, yet the world’s twenty largest pharma companies realized 80% of their growth as a result of exorbitant price hikes. Pharma currently enjoys its extraordinary profitability by exploiting the world’s most vulnerable populations. Yet even their ability to increase prices in the face of falling demand does not satisfy their profit demands. The breadth and depth of pharma’s marketing transgressions exceed those of any other industry and have now reached a point where authorities around the world have found it necessary to take legal action against its violations. Drastic change is needed if the pharmaceutical industry can equitably advance the health of the world’s population and regain public esteem. This book illustrates the range and extent of pharma’s violations and addresses the actions that should be implemented in order to make the drug industry a more constructive, less venal part of contemporary society. It will be of interest to researchers, academics, practitioners, and students with an interest in the pharmaceutical industry, healthcare management, regulation, and bioethics. |
| pathalys pharma: Drug Wars Robin Feldman, Evan Frondorf, 2017-06-09 While the shockingly high prices of prescription drugs continue to dominate the news, the strategies used by pharmaceutical companies to prevent generic competition are poorly understood, even by the lawmakers responsible for regulating them. In this groundbreaking work, Robin Feldman and Evan Frondorf illuminate the inner workings of the pharmaceutical market and show how drug companies twist health policy to achieve goals contrary to the public interest. In highly engaging prose, they offer specific examples of how generic competition has been stifled for years, with costs climbing into the billions and everyday consumers paying the price. Drug Wars is a guide to the current landscape, a roadmap for reform, and a warning of what is to come. It should be read by policymakers, academics, patients, and anyone else concerned with the soaring costs of prescription drugs. |
| pathalys pharma: The Antidote Barry Werth, 2014-02-04 In 1989, the charismatic Joshua Boger left Merck, then America's most admired business, to found a drug company that would challenge industry giants and transform health care. Journalist Barry Werth described the company's tumultuous early days during the AIDS crisis in The Billion-Dollar Molecule, a celebrated classic of science and business journalism. Now he returns to tell the story of Vertex's bold endurance and eventual success. The pharmaceutical business is America's toughest and one of its most profitable. It's riskier and more rigorous at just about every stage than any other business, from the towering biological uncertainties inherent in its mission to treat disease; to the 30-to-1 failure rate in bringing out a successful medicine; to the multibillion-dollar cost of ramping up a successful product; to operating in the world's most regulated industry, matched only by nuclear power. Werth captures the full scope of Vertex's 25-year drive to deliver breakthrough medicines.--From publisher description. |
| pathalys pharma: The Pharmaceutical Studies Reader Sergio Sismondo, Jeremy A. Greene, 2015-03-02 The Pharmaceutical Studies Reader is an engaging survey of the field that brings together provocative, multi-disciplinary scholarship examining the interplay of medical science, clinical practice, consumerism, and the healthcare marketplace. Draws on anthropological, historical, and sociological approaches to explore the social life of pharmaceuticals with special emphasis on their production, circulation, and consumption Covers topics such as the role of drugs in shaping taxonomies of disease, the evolution of prescribing habits, ethical dimensions of pharmaceuticals, clinical trials, and drug research and marketing in the age of globalization Offers a compelling, contextually-rich treatment of the topic that exposes readers to a variety of approaches, ideas, and frameworks Provides an accessible introduction for readers with no previous background in this area |
| pathalys pharma: The Body Hunters Sonia Shah, 2012-03-13 Hailed by John le Carré as “an act of courage on the part of its author” and singled out for praise by the leading medical journals in the United States and the United Kingdom, The Body Hunters uncovers the real-life story behind le Carré's acclaimed novel The Constant Gardener and the feature film based on it. A trenchant exposé . . . meticulously researched and packed with documentary evidence (Publishers Weekly), Sonia Shah's riveting journalistic account shines a much-needed spotlight on a disturbing new global trend. Drawing on years of original research and reporting in Africa and Asia, Shah examines how the multinational pharmaceutical industry, in its quest to develop lucrative drugs, has begun exporting its clinical research trials to the developing world, where ethical oversight is minimal and desperate patients abound. As the New England Journal of Medicine notes, “it is critical that those engaged in drug development, clinical research and its oversight, research ethics, and policy know about these stories,” which tell of an impossible choice being faced by many of the world's poorest patients—be experimented upon or die for lack of medicine. |
| pathalys pharma: The Price of Health Michael Kinch, Lori Weiman, 2021-04-06 From pharma bros to everday household budgets, just how did the pharmaceutical industry betray its own history—and how can it return to its tradition of care? It’s an unfortunate and life-threatening fact: one in five Americans has skipped vital prescriptions simply because of the cost. These choices are being made even though we have reached a point in the conveyance of medical options where cancers can be cured and sight restored for those blinded by rare genetic disorders. How, in this time of such advancements, did we reach a point, where people cannot afford the very things that could save their lives? As the COVID-19 global pandemic has pointed out, we need the leadership of scientists, researchers, public health officials and lawmakers alike to guide us through not only in times of a global health crisis, but also during far more mundane times. For the first time in decades, people from all walks of life face the same need for medicine. It is time to discuss the tough questions about drug pricing in an open, honest and, hopefully, transparent manner. But first we must understand how we, as a society, got here. Medicines are arguably the most highly regulated—and cost-inflated—products in the United States. The discovery, development, manufacturing and distribution of medicines is carried out by an ever more complex and crowded set of industries, each playing a part in a larger “pharmaceutical enterprise” seeking to maximize profits. But this was not always the case. The Price of Health is the reveals the story of how the pharmaceutical enterprise took shape and led to the present crisis. The reputation of the pharmaceutical industry is suffering from self-inflicted wounds and its continued viability, indeed survival, is increasingly questioned. Yet the drug makers do not shoulder all the blame or responsibility for the current price crisis. Deeply researched, The Price of Health gives us hope as to how we can still right the ship, even amidst the roiling storm of a global pandemic. How have medicines have been made and distributed to consumers throughout the years? What sea of changes that have contributed to rising costs? Some individuals, actions, and systems will be familiar, others may surprise. Yet the combined implications of these actions for will be surprising and at times shocking to both industry professionals and average Americans alike. Like so much else in human history, the history of the pharmaceutical enterprise is populated mostly by well-intended and even noble individuals and organizations. Each contributed to the formation or maintenance of structures meant to improve the quality and quantity of life through the development and distribution of medicines. And yet systems originally created to do good have often been subverted in ways contrary to the motivations of their creators. Only by understanding this disconnect can we better tackle the underlying problems of the industry head on, preventing foreseeable, and thus avoidable, medical calamities to come. |
| pathalys pharma: Deadly Medicines and Organised Crime Peter Gotzsche, 2019-08-21 PRESCRIPTION DRUGS ARE THE THIRD LEADING CAUSE OF DEATH AFTER HEART DISEASE AND CANCER. In his latest ground-breaking book, Peter C Gotzsche exposes the pharmaceutical industries and their charade of fraudulent behaviour, both in research and marketing where the morally repugnant disregard for human lives is the norm. He convincingly draws close co |
| pathalys pharma: Equitable Access to High-Cost Pharmaceuticals Zaheer-Ud-Din Babar, 2018-02-27 Equitable Access to High-Cost Pharmaceuticals seeks to aid the development and implementation of equitable public health policies by pharmaco-economics professionals, health economists, and policymakers. With detailed country-by country analysis of policy and regulation, the Work compares and contrasts national healthcare systems to support researchers and practitioners identify optimal healthcare policy solutions. The Work incorporates chapters on global regulatory changes, health technology assessment guidelines, and competitive effectiveness research recommendations from international bodies such as the OECD or the EU. Novel policies such as horizon scanning, managed-entry agreement and post-launch monitoring are considered in detail. The Work also thoroughly reviews novel pharmaceuticals with particular research interest, including cancer drugs, orphan medicines, Hep C, and personalized medicines. - Evaluates impact and efficacy of current access policies and pricing regulation of high-cost drugs - Incorporates existing guidelines and recommendations by international organizations - Compares and contrasts how different countries fund and police high-cost drug access - Explores novel and emergent policies, including managed entry agreement, analysis of real world data and differential pricing - Reviews novel pharmaceuticals of current research interest |
| pathalys pharma: Good Pharma Donald W. Light, Antonio F. Maturo, 2015-06-30 Drawing on key concepts in sociology and management, this history describes a remarkable institute that has elevated medical research and worked out solutions to the troubling practices of commercial pharmaceutical research. Good Pharma is the answer to Goldacre's Bad Pharma: ethical research without commercial distortions. |
| pathalys pharma: Driving Down the Cost of Drugs Ramón Castellblanch, 2012 How can health-access advocates beat the wealthy pharmaceutical industry, which has the biggest spending lobby in Washington? Ramón Castellblanch provides a ringside seat at the battle as he reveals how activists in Vermont, Maine, and California took on Big Pharma in their state legislatures to promote better and cheaper access to prescription drugs¿and ultimately pushed Congress to enact a Medicare prescription drug benefit. He also draws lessons from these cases about the possibilities for success elsewhere in the health policy arena, highlighting the crucial role that voters¿ righteous indignation plays in fueling popular support for grassroots political leaders who are taking on powerful business interests. |
| pathalys pharma: Devalued and Distrusted John L. LaMattina, 2012-12-10 An expert's view on solving the challenges confronting today's pharmaceutical industry Author John LaMattina, a thirty-year veteran of the pharmaceutical industry and former president of Pfizer's Global R&D Division, is internationally recognized as an expert on the pharmaceutical industry. His first book, Drug Truths: Dispelling the Myths About Pharma R&D, was critically acclaimed for clearing up misconceptions about the pharmaceutical industry and providing an honest account of the contributions of pharmaceutical research and development to human health and well-being. As he toured the country discussing Drug Truths, Dr. LaMattina regularly came across people who were filled with anger, accusing the pharmaceutical industry of making up diseases, hiding dangerous side effects, and more. This book was written in response to that experience, critically examining public perceptions and industry realities. Starting with 4 Secrets that Drug Companies Don't Want You to Know, Devalued and Distrusted provides a fact-based account of how the pharmaceutical industry works and the challenges it faces. It addresses such critical issues as: Why pharmaceutical R&D productivity has declined Where pharmaceutical companies need to invest their resources What can be done to solve core health challenges, including cancer, diabetes, and neurodegenerative diseases How the pharmaceutical industry can regain public trust and resuscitate its image Our understanding of human health and disease grows daily; however, converting science into medicine is increasingly challenging. Reading Devalued and Distrusted, you'll not only gain a greater appreciation of those challenges, but also the role that the pharmaceutical industry currently plays and can play in solving those challenges. Get to know the author: Read an interview with John LaMattina or watch a video on ChemistryViews! Interview: John LaMattina: 30 Years in Pharma Video: Can the Pharmaceutical Industry Restory its Broken Image? |
| pathalys pharma: The Law and Ethics of the Pharmaceutical Industry M.N.G. Dukes, 2005-11-04 As one of the most massive and successful business sectors, the pharmaceutical industry is a potent force for good in the community, yet its behaviour is frequently questioned: could it serve society at large better than it has done in the recent past? Its own internal ethics, both in business and science, may need a careful reappraisal, as may the extent to which the law - administrative, civil and criminal - succeeds in guiding (and where neccessary contraining) it. The rules of behavior that may be considered to apply to today's pharmaceutical industry have emerged over a very long period and the process goes on. Even the immensely detailed standards for quality, safety and efficacy laid down in drug law and regulation during the second half of the twentieth century have their limitations as tools for ensuring that the public interest is well served. In particular, national and regional regulatory agencies are heavily dependent on industrial data for their decision-making, their standards and competence vary, and even the existing network of agencies does not cover the entire world. What is more there are many areas of law and regulation affecting the industry, concerning for example the pricing of medicines, the conduct of clinical studies, the health protection of workers and concern for the environment. In some fields it is indeed hardly possible to maintain standards through regulation.Professor N.M. Graham Dukes, a physician and lawyer with long term experience in industrial research management, academic study and international drug policy, provides here a powerfully documented analysis into the way this industry thinks, acts, and is viewed, and examines the current trends pointing to change.*Provides a balanced picture of the current role of the pharmaceutical industry in society*Includes indices of conventions, laws, and regulations; as well as judicial and disciplinary cases*This is the only book addressing the legal implications of big pharma activities and ethical standards |
| pathalys pharma: Attrition in the Pharmaceutical Industry Alexander Alex, C. John Harris, Dennis A. Smith, 2015-10-26 With a focus on case studies of R&D programs in a variety of disease areas, the book highlights fundamental productivity issues the pharmaceutical industry has been facing and explores potential ways of improving research effectiveness and efficiency. Takes a comprehensive and holistic approach to the problems and potential solutions to drug compound attrition Tackles a problem that adds billions of dollars to drug development programs and health care costs Guides discovery and development scientists through R&D stages, teaching requirements and reasons why drugs can fail Discusses potential ways forward utilizing new approaches and opportunities to reduce attrition |
| pathalys pharma: Corporate Crime in the Pharmaceutical Industry (Routledge Revivals) John Braithwaite, 2013-10-08 First published in 1984, this book examines corporate crime in the pharmaceutical industry. Based on extensive research, including interviews with 131 senior executives of pharmaceutical companies in the United States, the United Kingdom, Australia, Mexico and Guatemala, the book is a major study of white-collar crime. Written in the 1980s, it covers topics such as international bribery and corruption, fraud in the testing of drugs and criminal negligence in the unsafe manufacturing of drugs. The author considers the implications of his findings for a range of strategies to control corporate crime, nationally and internationally. |
| pathalys pharma: Pharma-Ecology Patrick K. Jjemba, 2018-09-19 The revised edition of the guide to environmental impact of pharmaceuticals and personal care products The revised and updated second edition of Pharma-Ecology joins the health and environmental sciences professions' concern over the occurrence and fate of pharmaceutical and personal care products (PPCPs) in the environment and explores how to best minimize their impact. The text highlights the biological effects of various classes of pharmaceutical compounds under clinical settings, their modes of action, and approximate quantities consumed. The second edition contains the most recent knowledge about the ecological impact of PPCPs as more sensitive detection techniques have become available, since the book was first published. The second edition offers the most up-to-date information on pharma ecology and bridges the gap between medicine, public health, and environmental science. This new edition contains helpful learning objectives for each chapter, as well as a brief section at the end of each chapter that presents a set of open ended questions. This vital resource: • Explores the biological effects of pharmaceutical compounds under clinical settings, their modes of action, approximate quantities consumed • Provides researchers and scientists with critical background data on the environmental impacts of PPCPs • Contains the most current information on PPCPs' ecological impacts, based on new detection techniques • Bridges the gap between medicine, public health, and environmental science Written for ecologists, engineers, microbiologists, pharmacists, toxicologists, chemists, physicians, and veterinarians involved in pollution and environmental analysis, the second edition of Pharma-Ecology contains the most current information available on the environmental impact of pharmaceuticals and personal care products. |
| pathalys pharma: The Merck Druggernaut Fran Hawthorne, 2004-07-05 An in-depth look at big pharma's flagship company The Merck Druggernaut takes readers inside Merck, the world's second most profitable drug company and maker of the world's bestselling drug, Prilosec. Consistently named one of Fortune magazine's Most Admired Companies, Merck struggles to maintain its reputation for being the most ethical of the big drug makers, refusing to slash research and development budgets in the face of declining profits, falling stock market prices, and questionable accounting. Author Fran Hawthorne, one of the leading journalists covering healthcare, has written an excellent examination of a business paragon with much-needed insight on the cutthroat world of pharmaceuticals. It's a story that will interest the business world as well as consumer and healthcare advocates by detailing the vital issues in medicine and healthcare today. More than just a compelling story of success in a difficult industry, more than simply the biography of one of big business's most recognizable names, The Merck Druggernaut takes a thoughtful look at some of the major issues of our time and the way those issues intertwine with the world of business. Fran Hawthorne (New York, NY) is the Assistant Managing Editor at Crain's New York Business. She has been covering business for more than twenty years for such publications as Fortune, BusinessWeek, and Institutional Investor, with a prevailing interest in healthcare and pharmaceuticals. At Crain's, she spearheads the publication of two to three special healthcare issues per year. |
| pathalys pharma: Reasonable Rx Stan Finkelstein, Peter Temin, 2008-01-23 A Real Plan for Making Drugs Affordable–and Promoting Innovation, Too “This book is a necessity for understanding the pharmaceutical industry. Both the pluses and minuses of the present system are set forth with a judicious combination of historical narrative, economic analysis, and statistical data. The highly original proposals for reform will be a major stimulant to analysis and policy-making.” –Kenneth Arrow, Nobel Laureate in Economics, Professor Emeritus, Stanford University “This is a timely book by authors who know what they are talking about. They tackle a big problem: rising drug prices that are threatening to overwhelm us all–and especially those with limited or absent health care insurance. Will we drive people overseas for healthcare? Will there be social unrest? This book describes the problem and then offers a solution. Worth a careful read by everyone, pharmaceutical manufacturers and government policymakers especially.” –Roger Williams, M.D., Chief Executive Officer of the United States Pharmacopeia and a former senior official of the Food and Drug Administration “This book confounds two sets of skeptics: Those who say there’s no way to resolve the conflict between the need to fund pharmaceutical research and our desire to keep medicine affordable; and those who think that economics never has anything good to say.” –Honorable Barney Frank, Congressman from Massachusetts “This book comes at the right time and could become the starting point of discussions, which will eventually lead us into new era in the healthcare care industry. It will without a doubt become a must for insiders of the pharma- and biotech industries.” –Dr. Jürgen Drews, retired President of Roche Pharmaceutical Group Global Research Acknowledgments viii About the Authors ix Introduction xi Chapter 1: Drugs and Drug Prices 1 Chapter 2: The American Way to Discover Drugs 21 Chapter 3: The Drug Industry Today 39 Chapter 4: Are Drug Companies Risky? 59 Chapter 5: How Not to Lower Drug Prices 77 Chapter 6: Squandering R & D Resources 103 Chapter 7: How to Lower Drug Prices 129 Appendix: Our Solution in Detail 155 Index 177 |
| pathalys pharma: Sickening John Abramson, 2023-02-21 The inside story of how Big Pharma's relentless pursuit of ever-higher profits corrupts medical knowledge--misleading doctors, misdirecting American health care, and harming our health. The United States spends an excess $1.5 trillion annually on health care compared to other wealthy countries--yet the amount of time that Americans live in good health ranks a lowly 68th in the world. At the heart of the problem is Big Pharma, which funds most clinical trials and therefore controls the research agenda, withholds the real data from those trials as corporate secrets, and shapes most of the information relied upon by health care professionals. In this no-holds-barred exposé, Dr. John Abramson--one of the foremost experts on the drug industry's deceptive tactics--combines patient stories with what he learned during many years of serving as an expert in national drug litigation to reveal the tangled web of financial interests at the heart of the dysfunction in our health-care system. For example, one of pharma's best-kept secrets is that the peer reviewers charged with ensuring the accuracy and completeness of the clinical trial reports published in medical journals do not even have access to complete data and must rely on manufacturer-influenced summaries. Likewise for the experts who write the clinical practice guidelines that define our standards of care. The result of years of research and privileged access to the inner workings of the U.S. medical-industrial complex, Sickening shines a light on the dark underbelly of American health care--and presents a path toward genuine reform. |
| pathalys pharma: The Big Fix Katharine Greider, 2008-12-15 As the pharmaceutical industry invests more and more in the development of new drugs, true breakthroughs are few and far between. Into the breach comes a panoply of product-line extensions and me-too drugs aimed at grabbing market share. The industry plows its high profits back into research, but invests an equal or greater sum in flogging its products in every imaginable venue. Research studies are designed to support marketing claims. Many doctors all over the country get their first information about new drugs from a salesperson. And, increasingly, prescription drugs are pitched to consumers on TV and the internet with images of hope, terror, or chic. Evidence-based practice guidelines, which endeavor to get the right medicines to those who will benefit most, can't be heard over the din. Having created an unprecedented number of megabrands—blockbuster drugs with huge sales—and undergone an extraordinary wave of consolidation, some drug companies now find themselves in a precarious position. Patents are expiring on flagship products. In order to sustain the growth Wall Street has come to expect, these companies must produce billions of dollars worth of new revenue—fast. But can Americans continue to bankroll Operation Grow Big Pharma? Must we swallow the bad with the good? |
| pathalys pharma: Big Pharma, Big Greed (Second Edition) Stephen A Sheller, Sidney D Kirkpatrick, Christopher Mondics, 2021-06-08 UPDATED AND REVISED EDITION: Throughout his distinguished legal career, Stephen Sheller has relished the role of the underdog, evincing a sharply honed sense of fair play and justice. Early in his career, he represented Black Panthers in Philadelphia when they were arrested on trumped up murder and conspiracy charges. Later, he was in the vanguard of lawyers who took on the tobacco industry in the 1990s and he reprised that strategy a few years later in targeting Big Pharma for its harmful products and their deleterious effects on public health. In Big Pharma, Big Greed The inside story of one lawyer's battle to stem the flood of dangerous medicines and protect public health Sheller tells a tale that is at once deeply personal but also with wide repercussions for the U.S. health care system and the hundreds of millions of Americans whose lives literally depend on it. Decades of litigating against the pharmaceutical industry taught Sheller one irreducible lesson: In too many instances, unneeded and at times dangerous drugs are foisted on the public without adequate warning as to risks, all in the service of boosting industry profits. All too often, achieving block buster status for a patent protected medication becomes an end in itself, as Big Pharma companies manipulate clinical trial data, draft scholarly articles for friendly physicians often in their pay, and market their drugs for uses that never had been approved by the federal Food and Drug Administration. This last practice proved to be something of an Achilles Heel for the industry. In litigation that resulted in settlement and fines in the billions, companies such as Eli Lilly acknowledged marketing drugs off label to a broad range of patients for whom the medications had never been approved. Sheller's litigation formed the basis for these settlements and the effort is ongoing. He and other plaintiffs' lawyers now are suing Janssen Pharmaceuticals for the adverse impacts of its drug, Risperdal, a second generation anti-psychotic that Sheller and others allege is linked to the growth of female breast tissue in young boys and men. Already there have been several big jury verdicts against Janssen with hundreds of more cases yet to be tried. In the book, Sheller not only recounts his major litigation battles but also makes sweeping proposals for industry reform. To restore regulatory credibility, Sheller proposes that responsibility for testing new medicines be taken away from the industry and given over to hospitals and other public entities partnering with government regulators. Pharmaceutical companies that betray the public trust would risk government- initiated dissolution. Harsh medicine to be sure, but Sheller believes entirely appropriate to the underlying malady. |
| pathalys pharma: Pharma-Mafia Peter H., 2021-10-14 Das Buch ,,Pharma-Mafia von Dr. h.c. Peter Echevers H. stellt die Machenschaften der Pharma-Industrie ungeschönt an den Pranger. Aus unterschiedlichsten Quellen und auf der Basis jahrelanger Recherche reihen sich die Kapitel aneinander und zeigen auf, in welcher tatsächlichen Situation sich die Gesundheit jedes einzelnen von uns allen befindet. Wie glaubwürdig sind die Bekanntmachungen über neue Krankheiten, wie nützlich oder lebensgefährlich sind die neuen Impfungen? Was ist von Medikamenten zu halten, die althergebrachte ersetzen sollen? Geht es noch um den Patienten oder geht es ausschließlich darum, die Gier der großen Konzerne zu befriedigen, egal mit welchen Mitteln? Schonungslos, drastisch und eine Realität aufzeigend, die keiner wahrhaben will. Erfundene Seuchen, gefälschte Statistiken - nie zum Wohle des Kranken, aber immer zum Besten der Aktionäre und Pharma-Manager. |
| pathalys pharma: Pharmaceuticals, Corporate Crime and Public Health Graham Dukes, John Braithwaite, J P Moloney, 2014-06-27 The pharmaceutical industry exists to serve the community, but over the years it has engaged massively in corporate crime, with the public footing the bill. This readable study by experts in medicine, law, criminology and public health documents the pr |
| pathalys pharma: Blockbuster Drugs Jie Jack Li, 2013-12-02 For the world's largest prescription drug manufacturers, the last few years have been a harrowing time. Recently, Pfizer's Lipitor, GlaxoSmithKline's Advair, AstraZeneca's Seroquel, and Sanofi-Aventis and Bristol-Myers Squibb's Plavix all came off patent in the crucial U.S. market. This so-called patent cliff meant hundreds of billions of dollars in lost revenue and has pharmaceutical developers scrambling to create new drugs and litigating to extend current patent protections. Having spent most of his career in drug discovery in big pharma, Dr. Li now delivers an insider's account of how the drug industry ascended to its plateau and explores the nature of the turmoil it faces in the coming years. He begins with a survey of the landscape before blockbuster drugs, and proceeds to describe how those drugs were discovered and subsequently became integral to the business models of large pharmaceutical companies. For example, in early 1980s, Tagamet, the first blockbuster drug, transformed a minor Philadelphia-based drug maker named SmithKline & French into the world's ninth-largest pharmaceutical company in terms of sales. The project that delivered Tagamet was nearly terminated several times because research efforts begun in 1964 produced no apparent results within the first eleven years. Similar stories accompany the discovery and development of now-ubiquitous prescription drugs, among them Claritin, Prilosec, Nexium, Plavix, and Ambien. These stories, and the facets of the pharmaceutical industry that they reveal, can teach us valuable lessons and reveal many crucial aspects about the future landscape of drug discovery. As always, Dr. Li writes in a readable style and intersperses fascinating stories of scientific discovery with engaging human drama. |
| pathalys pharma: Pharmaceutical Care in Digital Revolution Claudia Rijcken, Ardalan Mirzaei, 2019-03-15 Pharmaceutical Care in Digital Revolution demonstrates how blending human and digital pharmaceutical care can establish optimal Apothecary Intelligence (AI). Organized into four parts, it examines digital health advances that will synergize the pharmaceutical care process and prepares stakeholders for a dynamic future, fueled with innovation. Beginning with the global picture on health care systems, patients' expectations, and current pharmaceutical care practices, the book covers details of relevant digital technologies as well as compliance, ethical, educational, and cultural aspects to take successful steps towards digital pharmaceutical care. The text includes links to lectures and technology facts, tutorials on how to implement advances in your own working environment, and examples of stakeholders who are successful in building synergy between digital and pharma. Pharmaceutical Care in Digital Revolution is a practical resource to equip pharmaceutical care stakeholders, such as pharmacists, physicians, pharmacy technicians, and students as well as those in surrounding ecosystems like payers or regulators. It is a crucial reference to understand how technological innovation is changing the paradigm in which we provide current and future pharmaceutical care and how to keep it accessible, affordable, and sustainable. - Learn about advances in digital health technology and apply them as a change leader to create circular pharmaceutical care - Provides insights on future pharmaceutical care and implement essential conditions to create the best outlook for patients - Access links, QR codes, and explanatory animations as educational material to the book |
| pathalys pharma: Big Pharma, Big Greed: The Inside Story of One Lawyer's Battle to Stem the Flood of Dangerous Medicines and Protect Public Health Sidney Kirkpatrick, Stephen Sheller, Christopher Mondics, 2019-02-11 |
| pathalys pharma: Bad Pharma Ben Goldacre, 2014-04-01 Bad Science hilariously exposed the tricks that quacks and journalists use to distort science, becoming an international bestseller. Now Ben Goldacre puts the $600bn global pharmaceutical industry under the microscope. What he reveals is a fascinating, terrifying mess. We like to imagine that medicine is based on evidence and the results of fair tests. In reality, those tests are often profoundly flawed. We like to imagine that doctors are familiar with the research literature about a drug, when in reality much of the research is hidden from them by drug companies. We like to imagine that doctors are impartially educated, when in reality much of their education is funded by pharmaceutical industry. We like to imagine that regulators let only effective drugs onto the market, when in reality they approve hopeless drugs, with data on side effects casually withheld from doctors and patients. All these problems have been protected from public scrutiny because they're too complex to capture in a sound bite. Ben Goldacre, however, shows that the true scale of this murderous disaster fully reveals itself only when the details are untangled. He believes we should all be able to understand precisely how data manipulation works and how research misconduct on a global scale affects us. With Goldacre's characteristic flair and a forensic attention to detail, Bad Pharma reveals a shockingly broken system and calls for something to be done. This is the pharmaceutical industry as it has never been seen before. |
| pathalys pharma: Global Pharmaceutical Policy Frederick M. Abbott, Maurice Nelson Graham Dukes, Graham Dukes, 2009-01-01 There is a strong argument that people throughout the world have a right to receive the medicines they need in an appropriate, affordable, and timely way. Global Pharmaceutical Policy describes the laws, policies, and customs relating to the development and provision of medicines, identifies their strengths and weakness, and then proposes global solutions for getting things better. Here is a masterpiece written in a clear and elegant style. Together, Dukes and Abbott have experience and insight that are unrivalled. Joe Collier, Emeritus Professor of Medicines Policy, St George s, University of London, UK Pharmaceuticals play a central role in health care throughout the world. The pharmaceutical industry is beset with difficulties as increasing research and development expenditure yields fewer new treatments. Public and private budgets strain under the weight of high prices and limited access. The world s poor see little effort to address diseases prevalent in less affluent societies, while the world s wealthy are overusing prescription drugs, risking their health and wasting resources. As the global economic crisis exacerbates pressure on health care budgets, a new presidential administration in Washington, DC has committed to broad health care reform. These circumstances form the backdrop for this extraordinarily timely examination of the global system for the development, production, distribution and use of medicines. The authors are acknowledged experts in the fields of pharmaceutical law and policy, with many years experience advising governments, multilateral organizations and policy-makers on issues involving innovation, access and use of medicines. Supported by a team of independent scientists, doctors and lawyers, they take an insightful look at the issues surrounding global regulation of the pharmaceutical sector, and offer pragmatic suggestions for reform. This book will be of interest to government policy-makers, members of industry, healthcare professionals, teachers, students and lawyers in the fields of public health, intellectual property and international trade. |
| pathalys pharma: First Do No Harm Walter Gratzer, 2017-09-19 The history of medicinal drugs extends back to the earliest human civilizations, when the search began for natural materialsplant, animal, or mineralthat might possess the power to cure, alleviate, or avert maladies or wounds. The quest continues still, conducted now by scientists and doctors in the thousands and in the shadow of big pharma. The story abounds with human interest, populated as it is with geniuses and charlatans, with the inspired and the deluded, with self-sacrifice and self-aggrandizement. Medicine over the centuries has been pervaded by false doctrines amounting to superstitions, the causes of endless misery and numberless death, and there were truths not recognized for decades and longer. Finally, industry, and its profit motive, has become an inescapable presence, which is sometimes a blessing to some or a curse to others, a source sometimes of corruption or sometimes of dazzling progress. Which of these predominates, it is up to the reader to judge. |
| pathalys pharma: Big Pharma Jacky Law, 2006-02-26 Last year, the pharmaceutical industry had sales in excess of 300 billion. Clearly, we all pay in one way or another — whether by buying drugs directly or through taxation. But it is less clear if we are getting value for our money. Author Jacky Law shows how a small number of corporations have come to dominate the global healthcare agenda. She reveals a system in which the relentless pursuit of profit is crowding out the public good. Effective regulators are under intense pressure from corporate lobbies, and companies spend more money on marketing than they spend on research and development. Meanwhile, the cost of new drugs rises relentlessly, while the number of original new products declines. All is not well with modern medicine. In what is both a diagnosis and a recommended course of treatment, Big Pharma reveals a world where market considerations, not medical need, are determining the research agenda. The author points to a future where the public and the medical profession once again have a voice in the kind of healthcare we want — and the healthcare we pay for. |
| pathalys pharma: Prescription Games Jeffrey Robinson, 2001 The major pharmaceutical companies, according to John le Carré – who has based his novel The Constant Gardener on their depredations – “are engaged in the systematic corruption of the medical profession, country by country.” Jeffrey Robinson can back up that charge. In Prescription Games, Jeffrey Robinson exposes the yawning abyss between the claims to altruism made by pharmaceutical companies and the harsh reality of their everyday practice. When the industry claims that the enormous markup they charge for new drugs pays the cost of developing new ones, they don’t say that as much as 80 per cent of R&D money is actually directed at developing drugs designed to compete with existing brands, or at creating variations on drugs whose patents are about to expire – expenditures only the industry itself (and its shareholders) will benefit from. Within the industry, there are “blockbuster” drugs that create vast wealth for the companies that manufacture them. Most are designed to treat conditions that are endemic among prosperous, western populations that can afford them. But there are no blockbuster drugs to treat diseases like tuberculosis, cholera, and malaria that ravage the Third World, because Third World countries can’t afford the prices. People in Africa and Asia die from new strains of tuberculosis while people in Europe and North America are offered expensive treatments for obesity, hair loss, and sexual dysfunction. In this hard-hitting exposé, Robinson also examines the extension of patent protection, the end of generic drug competition in Canada, the Nancy Olivieri scandal (how a drug manufacturer fought to conceal research findings that would damage sales of its product), the illicit drug trade, and espionage among drug manufacturers. |
| pathalys pharma: Generation Rx Greg Critser, 2005-10-07 This in-depth look at the rise of Big Pharma and pill marketing is “a page-turner” (Booklist, starred review). A finalist for a PEN America Literary Award for Research Nonfiction, this book takes a deep look at how the pharmaceutical industry—with some help from the medical and insurance fields and from American consumers themselves—has pushed its products, often at the expense of our health. Generation Rx reveals the roots of many of the widespread societal problems we face today, explaining how marketing efforts changed powerful chemical compounds for chronic diseases, once controlled by physicians, into substances we feel entitled to, whether we need them or not. Using exclusive interviews with the strategists, scientists, and current and former heads of GlaxoSmithKline, Eli Lilly, Merck, Roche, and more, the author of Fat Land presents a “fascinating and disturbing” story of business interests unleashed on an unsuspecting public, and a cultural shift that has caused lasting—and sometimes lethal—damage (New Scientist). “What Fast Food Nation did for the way Americans eat, Greg Critser does for the way we medicate ourselves.” —Michael Pollan, bestselling author of The Omnivore’s Dilemma |
| pathalys pharma: Pharmageddon David Healy, 2013-04 This searing indictment, David Healy’s most comprehensive and forceful argument against the pharmaceuticalization of medicine, tackles problems in health care that are leading to a growing number of deaths and disabilities. Healy, who was the first to draw attention to the now well-publicized suicide-inducing side effects of many anti-depressants, attributes our current state of affairs to three key factors: product rather than process patents on drugs, the classification of certain drugs as prescription-only, and industry-controlled drug trials. These developments have tied the survival of pharmaceutical companies to the development of blockbuster drugs, so that they must overhype benefits and deny real hazards. Healy further explains why these trends have basically ended the possibility of universal health care in the United States and elsewhere around the world. He concludes with suggestions for reform of our currently corrupted evidence-based medical system. |
Pathalys Pharma
Pathalys is a private, late-stage clinical biopharmaceutical company committed to the development of multiple advanced therapeutics that address unmet needs in the management …
Pathalys Pharma, Inc. Launches with Mission to Address High …
Mar 1, 2022 · Pathalys launches with a novel clinical-stage asset, upacicalcet, that was acquired through a license granted by EA Pharma for exclusive rights to the development and …
Pathalys Pharma secures $105M in financing to finalize
Aug 22, 2024 · Pathalys Pharma, fresh off raising an additional $105 million, is poised to finalize clinical trials and pursue regulatory approval for its treatment for patients with end-stage kidney …
Pathalys raises $105M to prepare kidney disease drug for FDA
Aug 20, 2024 · Pathalys Pharma has brought in $105 million via a series B fundraise that the kidney-disease-focused biotech will use to take its lead candidate through the final stages of …
Team – Pathalys Pharma
We are an experienced and highly motivated team focused on improving the lives of patients with chronic kidney disease through the development and improvement of therapeutic treatments.
Full List of Pharmaceutical Companies in North Carolina (2024)
Nov 1, 2023 · There are a huge number of biotech/pharmaceutical companies in North Carolina, with over 108 biomanufacturing sites, and over 730 life sciences companies.
Pathalys Pharma Raises $150 Million in Secured Product ... - Carlyle
Jan 18, 2023 · Pathalys Pharma, Inc. is a private, late-stage clinical biopharmaceutical company committed to the development of multiple advanced therapeutics that address unmet needs in …
Pathalys Pharma, Inc. Launches with Mission to Address High
Mar 1, 2022 · Pathalys Pharma, Inc. announced its formation made possible through initial seed financing from DaVita Venture Group, part of DaVita Inc., and Catalys Pacific.
Pathalys Pharma Raises $150 Million in Secured Product …
Jan 18, 2023 · Pathalys Pharma, Inc. is a private, late-stage clinical biopharmaceutical company committed to the development of multiple advanced therapeutics that address unmet needs in …
Pathalys Pharma Raises $150 Million in Secured Product …
Jan 18, 2023 · Pathalys Pharma, Inc. is a private, late-stage clinical biopharmaceutical company committed to the development of multiple advanced therapeutics that address unmet needs in …
Pathalys Pharma
Pathalys is a private, late-stage clinical biopharmaceutical company committed to the development of multiple advanced therapeutics that address unmet needs in the management …
Pathalys Pharma, Inc. Launches with Mission to Address High …
Mar 1, 2022 · Pathalys launches with a novel clinical-stage asset, upacicalcet, that was acquired through a license granted by EA Pharma for exclusive rights to the development and …
Pathalys Pharma secures $105M in financing to finalize
Aug 22, 2024 · Pathalys Pharma, fresh off raising an additional $105 million, is poised to finalize clinical trials and pursue regulatory approval for its treatment for patients with end-stage …
Pathalys raises $105M to prepare kidney disease drug for FDA
Aug 20, 2024 · Pathalys Pharma has brought in $105 million via a series B fundraise that the kidney-disease-focused biotech will use to take its lead candidate through the final stages of …
Team – Pathalys Pharma
We are an experienced and highly motivated team focused on improving the lives of patients with chronic kidney disease through the development and improvement of therapeutic treatments.
Full List of Pharmaceutical Companies in North Carolina (2024)
Nov 1, 2023 · There are a huge number of biotech/pharmaceutical companies in North Carolina, with over 108 biomanufacturing sites, and over 730 life sciences companies.
Pathalys Pharma Raises $150 Million in Secured Product ... - Carlyle
Jan 18, 2023 · Pathalys Pharma, Inc. is a private, late-stage clinical biopharmaceutical company committed to the development of multiple advanced therapeutics that address unmet needs in …
Pathalys Pharma, Inc. Launches with Mission to Address High
Mar 1, 2022 · Pathalys Pharma, Inc. announced its formation made possible through initial seed financing from DaVita Venture Group, part of DaVita Inc., and Catalys Pacific.
Pathalys Pharma Raises $150 Million in Secured Product …
Jan 18, 2023 · Pathalys Pharma, Inc. is a private, late-stage clinical biopharmaceutical company committed to the development of multiple advanced therapeutics that address unmet needs in …
Pathalys Pharma Raises $150 Million in Secured Product …
Jan 18, 2023 · Pathalys Pharma, Inc. is a private, late-stage clinical biopharmaceutical company committed to the development of multiple advanced therapeutics that address unmet needs in …
